AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03063255
Drug: Neuromuscular block
RxNorm normalized name: Neuromuscular blocking agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
Trial: NCT02296346
Drug: SoluMedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of drug subcutaneously, once a month.
Trial: NCT01722331
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to tildrakizumab PFS
Trial: NCT01853449
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01853449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline
Trial: NCT01686711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01357239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02330029
Drug: Ledebouriella Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledebouriella Root (\~10g)
Trial: NCT02330029
Drug: Fingered citron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingered citron (\~10g)
Trial: NCT02330029
Drug: Tuckahoe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuckahoe (15g)
Trial: NCT02330029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is blindly given to patients.
Trial: NCT03556761
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, PO, daily
Trial: NCT00325572
Drug: oral zinc and vitamin C supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
Trial: NCT00955240
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03894540
Drug: IPN60090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules given daily
Trial: NCT03876041
Drug: solumedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous solution for injection
Trial: NCT01054729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match sofosbuvir administered orally once daily
Trial: NCT01154166
Drug: ReQuip PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
Trial: NCT01154166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04603924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
Trial: NCT01850381
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
Trial: NCT01479049
Drug: HP (High potassium) group
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
Trial: NCT02441803
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
Trial: NCT03065530
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
Trial: NCT00950027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oropharyngeal decontamination every 4 hours
Trial: NCT02873221
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
Trial: NCT01325493
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
Trial: NCT01745055
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: individual dose of methotrexate (stably dosed)
Trial: NCT01351519
Drug: Aminolevulinic Acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
Trial: NCT02143271
Drug: KHK7580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT00142103
Drug: CPG10101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks
Trial: NCT00142103
Drug: CPG10101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks
Trial: NCT00142103
Drug: CPG10101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
Trial: NCT02203019
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest.
Trial: NCT00006168
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04579393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.
Trial: NCT00539721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
Trial: NCT04146532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 500mg placebo capsule.
Trial: NCT00163137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/day
Trial: NCT00772967
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Trial: NCT00772967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Trial: NCT01936337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical administration on psoriatic plaque
Trial: NCT02707757
Drug: Erythopoietin stimulating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
Trial: NCT01379586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
Trial: NCT02171715
Drug: BIBW 2992 MA2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated immediate release tablet - final formulation
Trial: NCT02171715
Drug: BIBW 2992 MA2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated immediate release tablet - trial formulation II
Trial: NCT04370262
Drug: SOC + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care treatment plus IV placebo
Trial: NCT00108810
Drug: Transdermal Ketoprofen Patch with CHADD
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 hours patch application for 28 days
Trial: NCT00108810
Drug: Placebo transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 hours application for 28 days
Trial: NCT04076761
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.
Trial: NCT00804440
Drug: Ibuprofen Tablets, 800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04653415
Drug: Tablet
RxNorm normalized name: TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
Trial: NCT04737720
Drug: Recombinant LCAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv infusion
Trial: NCT02334969
Drug: Naoxintong Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
Trial: NCT02334969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
Trial: NCT02612714
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
Trial: NCT01048515
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine capsule 6 mg/kg given 1 hour before test
Trial: NCT03531957
Drug: ASN002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of ASN002 for 12 weeks
Trial: NCT02627950
Drug: Morphinhydrochloricum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg morphine intravenously
Trial: NCT00385086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with placebo
Trial: NCT03851640
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01399827
Drug: ADHD Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
Trial: NCT00501852
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose dry-powder inhaler (SDDPI)
Trial: NCT00501852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose dry-powder inhaler (SDDPI)
Trial: NCT01221545
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.
Trial: NCT01221545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04210713
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/day
Trial: NCT01221298
Drug: ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT00010023
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02762864
Drug: Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
Trial: NCT02903511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring of safety and tolerability
Trial: NCT01225068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
Trial: NCT03312855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, intravenous application of Placebo solution
Trial: NCT00955110
Drug: Oxymorphone ER
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg or 30mg
Trial: NCT00955110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo was a sugar pill.
Trial: NCT04066881
Drug: Control PrEP:TDF/FTC once daily (weeks 0-26)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
Trial: NCT04066881
Drug: Experimental PrEP:TAF/FTC once daily (weeks 0-26)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
Trial: NCT01211964
Drug: LEO 22811
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of solution and tablet.
Trial: NCT01210768
Drug: Epirubicin+Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
Trial: NCT01210768
Drug: liposomal-doxorubicin+Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
Trial: NCT05126615
Drug: Auriculotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of a bolus of 5 μ of liquid nitrogen via a cryospray on the auriculotherapy points A4, C18, D9, C9, DIX, H13, G14 and FXVII, chosen according to a neurophysiological reasoning taking into account the surgical intervention performed and innervation of the anatomical region affected by the intervention.
Trial: NCT00693212
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing is identical to the MPH arm except that the pills will contain no active medication.
Trial: NCT02183467
Drug: BI 1356, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183467
Drug: BI 1356, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01893788
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 to 100 mg daily for 48 weeks
Trial: NCT02463591
Drug: Beriplex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beriplex 50 IU/Kg i.v. , single dose.
Trial: NCT03524872
Drug: Mouthwashes
RxNorm normalized name: MOUTHWASHES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
Trial: NCT00875420
Drug: RAD1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg Oral once a day for 28 days
Trial: NCT00875420
Drug: RAD1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Oral once a day for 28 days.
Trial: NCT00875420
Drug: RAD1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Oral once a day for 28 days
Trial: NCT00875420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral once a day for 28 days
Trial: NCT03750136
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose furosemide with hypertonic saline 3x daily
Trial: NCT03575130
Drug: Optive eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tears (placebo)
Trial: NCT00001259
Drug: Estradiol Patches
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal Estradiol, 100mcg/day by skin patch
Trial: NCT00001259
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by skin patch
Trial: NCT00001259
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given intramuscularly monthly
Trial: NCT00001259
Drug: Placebo suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal suppository
Trial: NCT04105140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration of placebo (24 IU)
Trial: NCT03440112
Drug: Clarithromycin (Not used as of 4/2020)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (generic) capsule 250mg each
Trial: NCT03440112
Drug: Placebo (Added 4/2020)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal placebo
Trial: NCT03199911
Drug: Topical Antibiotic Product
RxNorm normalized name: Betadine Antibiotic Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antibiotic ointment will be erythromycin or bacitracin. If the patient cannot obtain either (e.g. lack of availability at the pharmacy), bacitracin polymyxin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
Trial: NCT03199911
Drug: Topical Non-Antibiotic Ointment
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral oil/petrolatum-based artificial tear ointment.
Trial: NCT01972477
Drug: DLBS1449
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
Trial: NCT02484261
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg for age \< 8 years, 20 mg for age 8-\<13 years, 40 mg for ages \>14 years
Trial: NCT01401140
Drug: St Thomas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
Trial: NCT01401140
Drug: Custodiol
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
Trial: NCT03963544
Drug: oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR